172 results on '"Hurtz, Christian"'
Search Results
2. Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK
3. BCL6-Mediated Escape from Negative Selection Enables RAS-Driven B-Cell Transformation
4. Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition
5. SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia
6. Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia
7. Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition
8. Identification of BCL6 As Synthetic Lethality in RAS-Driven B-Cell Transformation
9. Alisertib Synergistically Strengthens the Anti-Leukemia Activity of Venetoclax in TCF3-Hlf B-ALL
10. Immunoglobulin Light Chains Control Permissiveness to Malignant B-Cell Transformation By RAS-Pathway Lesions
11. Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia
12. DYRK1A Is Required to Alleviate Replication Stress in KMT2A-Rearranged Acute Lymphoblastic Leukemia
13. Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL
14. Rationale for Targeting BCL6 in MLL-Rearranged B-ALL
15. DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A-Rearranged Acute Lymphoblastic Leukemia
16. Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation
17. Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic Leukemia
18. Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling
19. Redundant JAK, SRC and PI3 Kinase Signaling Pathways Regulate Cell Survival in Human Ph-like ALL Cell Lines and Primary Cells
20. Adaptive Reactivation of Signaling Pathways As a Novel Mechanism of Resistance to JAK Inhibitors in Ph-like ALL
21. BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation
22. Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-RearrangedAcute Lymphoblastic Leukemia
23. B-Lymphoid Transcription Factors Restrict Glycolytic Energy Supply for Oncogenic Signaling
24. Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia
25. Extrafollicular CD4+ T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center Formation
26. BCL6 Enables RAS-Driven Pre-B Cell Transformation in Acute Lymphoblastic Leukemia
27. Reciprocal Regulation of BCL6 and MLL Expression As a Vulnerability in MLL -Rearranged Acute Lymphoblastic Leukemia
28. Erk and Stat5 Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia
29. Lineage-Specific Metabolic Reprogramming Reveals LKB1 as Therapeutic Target in Acute Lymphoblastic Leukemia
30. IL2RA (CD25) Recruits Inhibitory Phosphatases to the Cell Membrane and Mediates Negative Feedback Control of STAT5 Signaling in Acute Lymphoblastic Leukemia
31. Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia
32. BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic Leukemia
33. PTEN Is Essential for Normal Cytokine Signaling and Oncogenic Transformation of Pre-B Cells
34. CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies
35. Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL
36. The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALL
37. Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia
38. Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL
39. Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL
40. SOX4 enables Oncogenic Survival Signals in Acute Lymphoblastic Leukemia
41. Targeting the UPR-Transcription Factor XBP1 to Overcome Drug-Resistance in Ph+ ALL
42. Ibrutinib inhibits pre-BCR+B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK
43. BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia
44. BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid Leukemia
45. BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia.
46. Alisertib Synergistically Strengthens the Anti-Leukemia Activity of Venetoclax in TCF3-HlfB-ALL
47. Reciprocal Regulation of BCL6and MLLExpression As a Vulnerability in MLL-Rearranged Acute Lymphoblastic Leukemia
48. Oncogenic Feedback Activation Between BCL6and MLLPromotes Malignant Transformation in MLL-RearrangedAcute Lymphoblastic Leukemia
49. Extrafollicular CD4+T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center Formation
50. PTENIs Essential for Normal Cytokine Signaling and Oncogenic Transformation of Pre-B Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.